A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, multi-center, placebo-controlled, parallel-group study will
evaluate the sustained virologic response and the safety of mericitabine (RO5024048) in
combination with boceprevir and Pegasys/Copegus in patients with chronic hepatitis C
infection. The anticipated time on study treatment is up to 48 weeks.